Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study

Saved in:
Bibliographic Details
Published inArchives of internal medicine (1960) Vol. 172; no. 15; p. 1182
Main Authors Caglayan, Evren, Axmann, Sarah, Hellmich, Martin, Moinzadeh, Pia, Rosenkranz, Stephan
Format Journal Article
LanguageEnglish
Published United States 13.08.2012
Subjects
Double-Blind Method
Drug Monitoring - methods
Female
Fingers - blood supply
Fingers - physiopathology
Half-Life
Humans
Imidazoles - administration & dosage
Imidazoles - adverse effects
Imidazoles - pharmacokinetics
Laser-Doppler Flowmetry - methods
Male
Phosphodiesterase 5 Inhibitors - administration & dosage
Phosphodiesterase 5 Inhibitors - adverse effects
Phosphodiesterase 5 Inhibitors - pharmacokinetics
Piperazines - administration & dosage
Piperazines - adverse effects
Piperazines - pharmacokinetics
Raynaud Disease - diagnosis
Raynaud Disease - drug therapy
Raynaud Disease - physiopathology
Regional Blood Flow - drug effects
Sulfones - administration & dosage
Sulfones - adverse effects
Sulfones - pharmacokinetics
Treatment Outcome
Triazines - administration & dosage
Triazines - adverse effects
Triazines - pharmacokinetics
Vardenafil Dihydrochloride
Online AccessGet more information

Cover

More Information
ISSN:1538-3679
DOI:10.1001/archinternmed.2012.2271